Done. Not a doctor or a scientist, but I posted:

Done. Not a doctor or a scientist, but I posted:

The pathogenicity of Covid, as in Ebola, is due to an overwhelming and disproportionate immune response, which results in the “cytokine storm”. The success in Britain of dexamethasone in severe
patients demonstrated that reducing immune over reaction can save lives. Target monoclonal antibodies will be a much more effective therapeutic, much less of the blunt tool, but moderately successful tool
of corticosteroids

Humanigen’s lenzilumab is promising, as it blocks GM-CSF stopping, the proliferation and differentiation of stem cells into macrophages, neutrophils, basophils, dendritic cells, and eosinophils.

Even more promising is leronlimab, which is a receptor site antibody of CCR5. Blocking CCR5 stops the trafficking of existing populations of the same macrophages, basophils, neutrophils and eosinophils to areas of inflammation, reversing the cytokine storm.

Additionally, leronlimab repolarizes macrophages to an anti inflammatory state and reverses exhaustion of CD8 T cells, so that they resume normal function, which includes production of granzyme-A, which lyses virally infected cells and eliminates viremia.

So no, none of these therapeutics block viral entry. TMPRSS2 blockers may at some point. However, as another poster noted, leronlimab has demonstrated efficacy in treating the immune dysregulation of Covid 19. In a phase 2 study, with P=0.02. Severe adverse events and progression to severe disease
were both markedly reduced.
We can wait years for RNA transcriptase inhibitors and TMPR22 blockers, or we can use leronlimab now, saving millions of lives and hundreds of billions of dollars.